Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, Marzella D, Testi AM, Foà R.

Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14. No abstract available.

2.

Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.

Mariani S, Giona F, Basciani S, Brama M, Gnessi L.

Lancet. 2008 Jul 12;372(9633):111-2. doi: 10.1016/S0140-6736(08)61023-5. No abstract available.

PMID:
18620939
3.

Bone metabolism during long-term treatment with imatinib.

O'Sullivan S, Horne A, Wattie D, Porteous F, Gamble G, Browett P, Grey A.

Leuk Lymphoma. 2013 Aug;54(8):1783-5. doi: 10.3109/10428194.2012.760734. Epub 2013 Jan 24. No abstract available.

PMID:
23278638
4.
5.

Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.

Dika E, Barisani A, Vaccari S, Fanti PA, Ismaili A, Patrizi A.

J Drugs Dermatol. 2013 May;12(5):512-3. No abstract available.

PMID:
23652942
6.

Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.

Machaczka M, Gossart M.

Pol Arch Med Wewn. 2013;123(5):251-2. No abstract available.

7.

Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, Watanabe A, Hotta N, Ito M, Kurosawa H, Kato K, Tsurusawa M, Horibe K, Shimada H.

J Pediatr. 2011 Oct;159(4):676-81. doi: 10.1016/j.jpeds.2011.03.046. Epub 2011 May 17.

PMID:
21592517
8.

Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.

Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S, Iland H.

Leuk Lymphoma. 2013 Jan;54(1):186-8. doi: 10.3109/10428194.2012.702904. Epub 2012 Aug 14. No abstract available.

PMID:
22712835
9.

A patient of chronic myelogenous leukemia developing painful rash on feet.

Kumar P, Das NK, Sil A, Chakrabarti P.

J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489. No abstract available.

10.

Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?

Cashen A, DiPersio JF, Khoury H.

J Clin Oncol. 2003 Nov 15;21(22):4255-6. No abstract available.

PMID:
14615462
11.

[Chronic myelogenous leukemia: management of treatment-related adverse events].

Takahashi N.

Rinsho Ketsueki. 2012 Oct;53(10):1581-8. Review. Japanese. No abstract available.

PMID:
23037730
12.

The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.

Eskazan AE, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.

Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6. No abstract available.

PMID:
24650055
13.

Multiple eruptive dermatofibromas related to imatinib treatment.

Llamas-Velasco M, Fraga J, Solano-López GE, Steegmann JL, García Diez A, Requena L.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):979-81. doi: 10.1111/jdv.12328. Epub 2013 Dec 10. No abstract available.

PMID:
24321053
14.

Vocal fold hemorrhage in a CML patient after Glivec treatment.

Shim HS, Woo SH.

Acta Oncol. 2013 May;52(4):866-8. doi: 10.3109/0284186X.2012.728715. Epub 2012 Nov 15. No abstract available.

PMID:
23153030
15.

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.

Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT.

Am J Hematol. 2015 Apr;90(4):E66-72. doi: 10.1002/ajh.23938. Epub 2015 Jan 30.

16.

Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.

Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR.

J Clin Oncol. 2013 Jul 1;31(19):2460-8. doi: 10.1200/JCO.2012.46.8280. Epub 2013 May 28.

PMID:
23715577
17.

Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.

Reksodiputro AH, Syafei S, Prayogo N, Karsono B, Rinaldi I, Rajabto W, Mulansari NA.

Acta Med Indones. 2010 Jan;42(1):2-5.

18.

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.

Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M.

Med Sci Monit. 2012 Dec;18(12):CR721-8.

19.

Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.

Smith BD.

J Natl Cancer Inst. 2011 Apr 6;103(7):527-9. doi: 10.1093/jnci/djr073. Epub 2011 Mar 21. No abstract available.

PMID:
21422404
20.

Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.

Mabed M, Elhefni AM, Damnhouri G.

Leuk Lymphoma. 2012 Nov;53(11):2310-1. doi: 10.3109/10428194.2012.680452. Epub 2012 Apr 30. No abstract available.

PMID:
22462614

Supplemental Content

Support Center